Introduction
============

Craniofacial development in mammals is the result of a series of complex environmental and genetic factors ([@b1-mmr-20-04-3326]), and cleft palate (CP) is one of the most common types of craniofacial malformation in humans ([@b2-mmr-20-04-3326]). This congenital deformity is due to the disruption of palatal genesis, which involves multiple cellular processes, including the proliferation of mesenchymal cells and growth of bilateral palate shelves ([@b3-mmr-20-04-3326]). Embryonic palate mesenchymal (EPM) cells derive from cranial neural crest cells, which are composed of pluripotent stem cells that can proliferate and differentiate into distinct craniofacial cells during palatal morphogenesis ([@b4-mmr-20-04-3326]). Any perturbations during EPM cell proliferation, differentiation and apoptosis can result in CP ([@b3-mmr-20-04-3326]).

Maternal conditions during gestation have a direct impact on fetal growth; they affect the fetus through the nutrients that reach the fetus via the placenta ([@b5-mmr-20-04-3326]). Nutrients beneficial for growth, as well as toxic substances, can thus be transported from the mother to the fetus ([@b6-mmr-20-04-3326]). There is ample evidence demonstrating that smoking, intake of various medications, presence of fever or flu, and a lack of adequate folic acid and other vitamins during pregnancy are risk factors for CP ([@b7-mmr-20-04-3326]--[@b10-mmr-20-04-3326]). Several studies have demonstrated that various metabolites can be transferred across the placenta during pregnancy ([@b11-mmr-20-04-3326]--[@b16-mmr-20-04-3326]). Dubé *et al* ([@b14-mmr-20-04-3326]) revealed that maternal obesity is associated with placental weight and increased levels of cholesterol and lipoprotein in the newborn. Paolini *et al* ([@b16-mmr-20-04-3326]) collected blood samples from fetuses after administering stable isotopes to their mothers. The results demonstrated that isotope-labeled amino acid levels, including leucine and phenylalanine, are significantly lower in the intrauterine growth-restricted group compared with the control group.

Dexamethasone (DXM) is a glucocorticoid that is often used to treat a range of diseases, including asthma, allergies, rheumatoid arthritis and inflammatory bowel disease (<https://www.chemicalbook.com>). Corticosteroids administered early in pregnancy have been reported to be associated with a fetal orofacial cleft ([@b17-mmr-20-04-3326]). Accordingly, corticosteroids are well-established experimental teratogens in animal CP models ([@b18-mmr-20-04-3326]--[@b20-mmr-20-04-3326]). The mechanisms by which corticosteroids may induce CP remain uncertain. However, previous studies have revealed that DXM serves a role in the progress of palatal fusion and restrains EPM cells from proliferation and apoptosis, while also affecting the differentiation of medial edge epithelial cells ([@b21-mmr-20-04-3326],[@b22-mmr-20-04-3326]).

High-spatial-resolution ^1^H magnetic resonance spectroscopy (MRS) is a non-invasive method to profile metabolites ([@b23-mmr-20-04-3326]). Compared with lower magnetic field strengths, ultra-high field strengths, including 7-Tesla (T) and 9.4T, provide a higher spectral resolution and signal-to-noise ratio, which significantly enhances the information obtained from these spectra. In the last few years, this approach has mainly been used to study biochemical alterations in neurology, including neurodegeneration and brain tumors ([@b24-mmr-20-04-3326]--[@b28-mmr-20-04-3326]). Since the proton is one of the most sensitive nuclei for MRS and nearly all metabolites contain hydrogen atoms, investigation by ^1^H MRS provides an opportunity to test tissue metabolites non-invasively. Therefore, researchers have utilized high-spatial-resolution ^1^H MRS to investigate metabolic alterations in the uterus leading to congenital diseases.

Song *et al* ([@b29-mmr-20-04-3326]) used ^1^H MRS to calculate placental metabolism in relation to intrauterine growth restriction; N-acetyl aspartate and choline levels decreased in comparison with normal placental levels, whereas lipids appeared to increase. Song *et al* ([@b29-mmr-20-04-3326]) therefore concluded that choline and lipids could serve as potential biomarkers to predict pregnancy outcomes. Zhou *et al* ([@b30-mmr-20-04-3326]) concluded that an ^1^H MRS-based metabolomics approach could be an efficient and convenient technique to differentiate individuals with oral squamous cell carcinoma from healthy controls. Additionally, researchers have attempted to identify the irregular metabolic profile of CP mouse models using *in vivo* 7T ^1^H MRS, and revealed that elevated lipid and choline levels in CP tissues may have the potential to serve as biomarkers of craniofacial congenital malformations ([@b31-mmr-20-04-3326]).

Based on the aforementioned findings, the present study used 9.4T MRS to identify the alterations in metabolites in maternal organs and fetal palatal tissues. The present study demonstrated the effects of small molecular metabolites in multiple organs that interact to promote the occurrence of CP in embryos.

Materials and methods
=====================

### Animal experiments

A total of 40 female and 20 male 8-week-aged Kunming mice, weighing 30 g, were raised in a standardized laboratory animal room (22--25°C; 70% humidity; 12-h light/dark cycle; food and water *ad libitum*). All experimental animals were provided by the Center for Laboratory Animal Sciences of Shantou Medical University. Female mice were mated with fertile males overnight (2 females: 1 male). The day on which vaginal plugs were observed was defined as embryonic gestation day 0.5 (E0.5). A total of 24 gestational females were randomly divided into two groups. Between E8.5 and E13.5, the treatment group was administered DXM (Jiangsu Chengxin Pharmaceutical Co., Ltd.) as 8 mg/kg twice per day by subcutaneous injection. At the same time, the control group was injected with the same volume normal saline. The present study was approved by the Animal Ethics Committee of Shantou University Medical College (Shantou, China).

### Preparation of samples

Cesarean sections were performed on pregnant mice on day E14.5, and the fetuses were explanted. Samples, including the serum of maternal mice, amniotic fluid and placenta tissues, and palatal tissues of fetal mice (only mice with anatomical CP were chosen for the experimental group), were collected for 9.4T MRS analyses.

A total of 30--40 mg placental and palatal tissues of each female mouse were divided evenly into two samples. Amniotic fluid and serum were centrifuged at 352 × g for 10 min at 4°C to remove particulate contaminants. Following cryopreservation in liquid nitrogen, the samples were stored at −80°C.

Tissue samples were homogenized by ultrasound, and 1.5 ml sonicate was extracted using a mixture of methanol and chloroform (2:1 v:v). This was followed by a centrifugation step (0°C, 1,891 × g, 20 min) in order to separate the water- and fat-soluble layers. Hydrophilic and lipophilic metabolites, respectively, were acquired when the solvents were removed by lyophilization and evaporated with nitrogen gas. The water-soluble metabolites were reconstituted in 600 µl D~2~O containing 0.5 mM 3-(trimethylsilyl) propionic-2,2,3,3-d4 acid sodium salt (TSP), while the lipid-soluble metabolites were reconstituted in 600 µl deuterated chloroform (CDCl~3~; 0.03% v/v trimethylsilyl).

Each bio-fluid sample (300 µl) was mixed with 250 µl D~2~O and 200 µl PBS (0.2 M Na~2~HPO~4~/NaH~2~PO~4~; pH 7.4; 99.9% D~2~O) to reduce the variations in pH across samples. Additionally, 0.3 mM TSP was used as an internal reference standard.

### Metabolomic measurements by 9.4T nuclear magnetic resonance (NMR)

The samples were analyzed by a 9.4T NMR spectrometer (Bruker Avance). After autoshimming, a ZGPR pulse sequence was used (number of scans: 64; mixing time: 100 µsec; spectral width: 13.9 ppm; time domain:16K; delay 11.5 sec). Weak irradiation on the water signal was applied to suppress solvents. Chemical shifts in all samples were referenced to TSP. All spectra detected by the 9.4T NMR spectrometer were processed using MestReNova version 9.0.1 software (Mestrelab Research, S.L.). The spectral range between 0.5 and 9.0 ppm was segmented into buckets with equal widths of 0.002 ppm each. Each bucket was internally normalized to the total sum of the spectral integrals prior to pattern recognition analysis to compensate for differences in sample concentration. For the data analyses, metabolites in all ^1^H-NMR spectra were assigned with reference to published data and Chenomx NMR suite version 7.1 (Chenomx, Inc.).

### Statistical analysis

Experimental data were processed using SIMCA-P version 14.1 software (Umetrics; Sartorius Stedim Biotech) for multivariate statistical analysis. First, principal component analysis (PCA) classing was used for an overview of the data. Next, the data were further analyzed via orthogonal partial least squares discriminant analysis (OPLS-DA). The model quality was evaluated using the R^2^Y and Q^2^ values, reflecting the explained model analytical ability and predictability, respectively. An R^2^Y score of 1 demonstrated that the model explained 100% of the variance, and the closer the Q^2^ score was to 1 the higher the reliability of prediction. To validate the quality of the OPLS-DA model, permutation tests with 200 iterations were performed. The criteria for validity were as follows: All blue Q^2^-values to the left are lower than the original points to the right, or the blue regression line of the Q^2^-points intersects the vertical axis (on the left) at ≤0.

Data of 12 DXM-treated samples and 12 control samples were used for multivariate statistical analysis. VIP (variable importance in projection) predictive values that had passed the permutation tests were obtained based on the OPLS-DA model. A Student\'s unpaired t-test was performed automatically during OPLS analysis. Data are presented as the mean ± standard deviation. Those metabolites corresponding to different ppm with P-values ≤0.05 and VIP values ≥1 were defined as significantly different.

### Histological sections

Palates of the embryos were harvested at E14.5 and processed in paraffin wax. Histological sections of embryonic palates were cut and stained with hematoxylin and eosin.

Palate of the embryos were harvested at E14.5 and fixed in 4% paraformaldehyde for at ≥24 h at room temperature, then they were dehydrated through an ethanol series and embedded in paraffin for sectioning by routine procedures. Deparaffinized sections (3 µm) were stained with 0.25% hematoxylin and 0.5% eosin for 3 min respectively at room temperature. For general morphology, stained sections were viewed by light microscope.

Results
=======

### Histological appearance of clefts

A total of 289 embryo mice were harvested with a 100% live birth rate. Among the 137 embryos exposed to DXM, 72 developed CPs, giving a CP-induction rate of 52.6% ([Fig. 1A and B](#f1-mmr-20-04-3326){ref-type="fig"}). None of the 152 murine embryos from the 12 pregnant mice treated with normal saline developed a CP.

The E14.5 embryos in the control group exhibited bilaterally elevated shelves. These touched at an epithelial line between them. The tongue was located between the bilateral lower mandibles and palate shelves ([Fig. 1C](#f1-mmr-20-04-3326){ref-type="fig"}). The majority of the DXM-exposed embryos, however, exhibited vertically oriented shelves. The tongues were much higher in the experimental group compared with in the control group ([Fig. 1D](#f1-mmr-20-04-3326){ref-type="fig"}).

Hydrophilic metabolic alterations observed in multiple organs
-------------------------------------------------------------

### Palatal tissue

Representative ^1^H NMR spectra of the palatal tissue obtained from one of the maternal mice at E14.5 are shown in [Fig. 2](#f2-mmr-20-04-3326){ref-type="fig"}. The palatal tissue spectrum contained peaks mainly representing amino acids, glutamate-containing metabolites and carboxylic acids, including citrate. The metabolic resonances were assigned according to a previous study ([@b32-mmr-20-04-3326]) and the Chenomx NMR suite (Chenomx NMR suite version 7.1 (Chenomx, Inc.). The identification of metabolites is shown in [Table I](#tI-mmr-20-04-3326){ref-type="table"}.

PCA score plots revealed the inherent clustering of groups based on their similarity and dissimilarity, indicating a clear distinction between the control and experimental groups ([Fig. 3A](#f3-mmr-20-04-3326){ref-type="fig"}). The significance of the differences between the two groups was further confirmed by an OPLS-DA test (R^2^Y=0.997; Q^2^=0.913; [Fig. 3B](#f3-mmr-20-04-3326){ref-type="fig"}). The results of 200 permutation tests ([Fig. 3C](#f3-mmr-20-04-3326){ref-type="fig"}) demonstrated that this model was reliable and consistent. The metabolites responsible for the significant separations between the two groups were identified using volcano plots ([Fig. 3D](#f3-mmr-20-04-3326){ref-type="fig"}). The present study identified lower levels of creatinine + creatine, leucine, valine, acetate and citrate, and higher levels of lactate, alanine, proline + inositol and glutamate-containing metabolites in the CP embryos. Detailed statistical descriptions of all alterations are shown in [Table II](#tII-mmr-20-04-3326){ref-type="table"}.

### Placental tissue

The data from placental tissues also revealed a significant intergroup distinction, which was demonstrated by the PCA and OPLS-DA score plots ([Fig. 4A and B](#f4-mmr-20-04-3326){ref-type="fig"}). The R^2^Y and Q^2^ values of the placental tissue OPLS-DA model were 0.930 and 0.524, respectively; the reliability of this model also passed a permutation test ([Fig. 4C](#f4-mmr-20-04-3326){ref-type="fig"}). According to the volcano plot ([Fig. 4D](#f4-mmr-20-04-3326){ref-type="fig"}) and the resolved results of NMR spectra ([Table II](#tII-mmr-20-04-3326){ref-type="table"}), the alteration in valine for the experimental group was similar to that found in the palatal tissue, but the levels of glutamate-containing metabolites were decreased, which was the opposite of what was observed in the palatal tissues. Certain metabolite levels were abnormal in placental tissues but normal in palatal tissues. In particular, succinate levels were lower in the experimental group. Notably, choline and its primary and secondary metabolites, including phosphorylcholine, betaine and trimethylamine N-oxide (TMAO), were also found at reduced levels in the experimental group.

### Amniotic fluid

Inherent clustering of groups and the model tests are shown in [Fig. 5](#f5-mmr-20-04-3326){ref-type="fig"}. A trend similar to that in the choline-containing metabolites of the placental tissue was found in the amniotic fluid. There was a decline in the experimental group, but the TMAO levels did not show any significant alterations. Additionally, alanine, creatinine, taurine, α-glucose and hippurate were present at lower levels in the experimental group, whereas lactate levels were elevated ([Table III](#tIII-mmr-20-04-3326){ref-type="table"}, table only shows significantly changed metabolites).

### Serum of maternal mice

Although the score plot of PCA showed less distinction, the model of OPLS-DA was still with satisfactory credibility and predictability ([Fig. 6](#f6-mmr-20-04-3326){ref-type="fig"}); three varying metabolites were found in the serum of maternal mice. Glutamine levels were lower in the experimental mice, whereas citrate and creatine levels were increased. These alterations are shown in [Table III](#tIII-mmr-20-04-3326){ref-type="table"}.

### Lipophilic metabolic alterations in multiple organs

The results of PCA, OPLS-DA and permutation tests, and differentiated metabolites of the corresponding tissues are shown in [Fig. 7](#f7-mmr-20-04-3326){ref-type="fig"}. In palatal and placental tissues, cholesterol and lipid levels were significantly different. Generally, the relative concentrations of cholesterol and lipids in palatal tissues of the DXM group were higher compared with those of the control group, except for (CH~2~)n lipid concentrations, which were lower. In the placental tissues, the alterations in cholesterol levels exhibited the opposite trend. Nevertheless, lipid levels for the different lipid forms varied and most of them were unsaturated lipids ([Table IV](#tIV-mmr-20-04-3326){ref-type="table"}).

Discussion
==========

The present study identified differences in the metabolites of DXM-induced CP tissues and other organs using ultra-high-field strength MRS at 9.4T, which uncovered an association between maternal metabolic conditions and fetal CP. Based on these findings, it was hypothesized that a diagnostic method may be developed, which, using 9.4T MRS, could detect the levels of metabolites in maternal body fluids.

DXM is commonly used as an anti-inflammatory and immunosuppressive medication that may occasionally be administered to pregnant women. Clinical studies have shown that it can cross the placenta intact and may therefore affect the developing fetus ([@b21-mmr-20-04-3326],[@b33-mmr-20-04-3326]--[@b35-mmr-20-04-3326]). Antenatal pharmacotherapy with corticosteroids can reduce the morbidity and mortality due to neonatal respiratory distress syndrome by improving lung maturation ([@b35-mmr-20-04-3326]--[@b37-mmr-20-04-3326]). As a side effect, corticosteroid administration to pregnant women can cause their fetuses to develop craniofacial deformities. There is evidence that systemic administration of DXM during the early stages of pregnancy is associated with the development of CP in humans ([@b6-mmr-20-04-3326],[@b21-mmr-20-04-3326],[@b34-mmr-20-04-3326],[@b38-mmr-20-04-3326],[@b39-mmr-20-04-3326]). Generally, autoimmune diseases do not affect fertility ([@b40-mmr-20-04-3326]). Treatments with DXM, however, may have an impact on birth outcomes.

Metabolomics has the ability to detect early dysregulation of metabolism associated with disease. The present study investigated these alterations via *in vitro* testing using 9.4T MRS involving DXM-induced CP mice, and indicated that their palatal tissue contained significantly increased levels of alanine, glutamate and glutamate-containing metabolites compared with the tissue of mice in the control group. However, the concentrations of valine tended to be lower compared with those of normal controls.

Increases in glutamate may be an indication of the reduced role of amino acids in the formation of the neural system. Glutamate has been reported to be associated with brain metabolites and can be measured with a 9.4T MRS imager ([@b41-mmr-20-04-3326],[@b42-mmr-20-04-3326]). Glutamate is known to be a major excitatory neurotransmitter in the central nervous system and is closely associated with a number of nervous system diseases ([@b42-mmr-20-04-3326],[@b43-mmr-20-04-3326]). γ-aminobutyric acid (GABA), the principal inhibitory neurotransmitter in the nervous system, is a product of glutamate ([@b44-mmr-20-04-3326]). GABA is also considered to serve a role in the formation of the nervous system ([@b45-mmr-20-04-3326],[@b46-mmr-20-04-3326]). Studies have reported that the 67-kDa isoform of glutamic acid decarboxylase (GAD67) and GAD67-derived GABA are involved in the formation of the palate ([@b47-mmr-20-04-3326],[@b48-mmr-20-04-3326]). Phosphocholine has been studied in regard to its association with cell membrane phospholipid metabolism ([@b31-mmr-20-04-3326],[@b48-mmr-20-04-3326]). The MRS data presented in the current study demonstrated that the choline and phosphorylcholine levels in the placentas of the experimental models were decreased significantly compared with those of the normal controls. This could be interpreted as reflecting an alteration in the cell membrane metabolism of subjects. Therefore, the data suggested that a quantitative test of amino acids, choline and phosphocholine lipids conducted by 9.4T MRS may serve as a prenatal test to determine potential craniofacial deformities.

Although they are limited, the results of the present study are informative and provide a basis for further studies. More research is required to clarify the interactions of these metabolites and their effects on multiple organs. The present study revealed that there is an association between maternal metabolites and the development of CP, but more studies are required to address the functions of these amino acids, specifically phosphocholine and lipids. Furthermore, since the results of the present study cannot suffice to prove the feasibility of a prenatal diagnostic method, several additional studies will be conducted in the future to address this question. Additionally, the findings of abnormal data were based on a comparison of experimental models and normal controls. In order to apply these findings clinically and enable prenatal examinations in human subjects, the reference values of maternal metabolites in humans will have to be determined.

In conclusion, the present study demonstrated that there is an association between the state of maternal metabolites and the subsequent formation of fetal CP. This finding provides a foundation for a possible diagnostic method using ultra-high field-strength MRS to test maternal metabolites, and thus, to identify fetuses with CP.
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![Palate of DXM-treated embryos and normal controls. (A) Gross appearance of palate of the normal controls at E14.5. (B) Gross appearance of palate of DXM-treated embryos at E14.5. The arrow indicates the cleft of palate. (C) Morphology of palate of the normal controls visualized by H&E staining at E14.5 (magnification, ×10). (D) Morphology of palate of the DXM-treated embryos visualized by H&E staining at E14.5 (magnification, ×10). DXM, dexamethasone; E14.5, embryonic gestation day 14.5; H&E, hematoxylin and eosin.](MMR-20-04-3326-g00){#f1-mmr-20-04-3326}

![Typical 9.4T ^1^H-NMR standard spectra of palate collected from DXM-treated and normal mice. Palate NMR spectra from a control pregnant mouse (red) and a DXM-treated pregnant mouse (blue). The x-axis represents chemical shift (ppm) and the y-axis represents coupling constants. Metabolite identification is shown in [Table I](#tI-mmr-20-04-3326){ref-type="table"}. 9.4T, 9.4-Tesla; DXM, dexamethasone; NMR, nuclear magnetic resonance.](MMR-20-04-3326-g01){#f2-mmr-20-04-3326}

![Multivariate statistical analysis of water-soluble metabolites of the palate tissue in the control and experimental groups. (A) PCA score plot based on control (green dots) and DXM samples (blue dots). 'Scores t1' represents scores of samples on principal component 1 and 'scores t2' represents scores of samples on principal component 2. (B) OPLS-DA score plot based on control (green dots) and DXM samples (blue dots). R^2^Y=0.997, Q^2^=0.913. (C) Statistical validation of OPLS-DA model by permutation testing (200 iterations). (D) Volcano score plot based on OPLS-DA model. Blue dots represent P≤0.05 and fold-change \<0. Red dots represent P≤0.05 and fold-change \>0. Green dots represent no statistically significant difference. The diameter of the dots represents the VIP value. DXM, dexamethasone; OPLS-DA, orthogonal partial least squares discriminant analysis; PCA, principal component analysis; VIP, variable importance in projection.](MMR-20-04-3326-g02){#f3-mmr-20-04-3326}

![Multivariate statistical analysis of water-soluble metabolites of placenta tissues of the control and experimental groups. (A) PCA score plot based on control (green dots) and DXM (blue dots) samples. 'Scores t1' represents the scores of samples on principal component 1 and 'scores t2' represents the scores of samples on principal component 2. (B) OPLS-DA score plot based on control (green dots) and DXM (blue dots) samples. R^2^Y=0.930, Q^2^=0.524. (C) Statistical validation of OPLS-DA model by permutation testing (200 iterations). (D) Volcano score plot based on OPLS-DA model. Blue dots represent P≤0.05 and fold-change \<0. Red dots represent P≤0.05 and fold-change \>0. Green dots represent no statistically significant difference. The diameter of the dots represents the VIP value. DXM, dexamethasone; OPLS-DA, orthogonal partial least squares discriminant analysis; PCA, principal component analysis; VIP, variable importance in projection.](MMR-20-04-3326-g03){#f4-mmr-20-04-3326}

![Multivariate statistical analysis of water-soluble metabolites of amniotic fluid of the control and experimental groups. (A) PCA score plot based on control (green dots) and DXM (blue dots) samples. 'Scores t1' represents the scores of samples on principal component 1 and 'scores t2' represents the scores of samples on principal component 2. (B) OPLS-DA score plot based on control (green dots) and DXM (blue dots) samples. R^2^Y=0.985, Q^2^=0.824. (C) Statistical validation of OPLS-DA model by permutation testing (200 iterations). (D) Volcano score plot based on OPLS-DA model. Blue dots represent P≤0.05 and fold-change \<0. Red dots represent P≤0.05 and fold-change \>0. Green dots represent no statistically significant difference. The diameter of the dots represents the VIP value. DXM, dexamethasone; OPLS-DA, orthogonal partial least squares discriminant analysis; PCA, principal component analysis; VIP, variable importance in projection.](MMR-20-04-3326-g04){#f5-mmr-20-04-3326}

![Multivariate statistical analysis of water-soluble metabolites of serum of the control and experimental groups. (A) PCA score plot based on control (green dots) and DXM (blue dots) samples. 'Scores t1' represents scores of samples on principal component 1 and 'scores t2' represents scores of samples on principal component 2. (B) OPLS-DA score plot based on control (green dots) and DXM (blue dots) samples. R^2^Y=0.947, Q^2^=0.656. (C) Statistical validation of OPLS-DA model by permutation testing (200 iterations). (D) Volcano score plot based on OPLS-DA model. Blue dots represent P≤0.05 and fold-change \<0. Red dots represent P≤0.05 and fold-change \>0. Green dots represent no statistically significant difference. The diameter of dots represents the VIP value. DXM, dexamethasone; OPLS-DA, orthogonal partial least squares discriminant analysis; PCA, principal component analysis; VIP, variable importance in projection.](MMR-20-04-3326-g05){#f6-mmr-20-04-3326}

![Multivariate statistical analysis of lipid-soluble metabolites of palate and placenta tissues of the control and experimental groups. (A) PCA score plot of palate tissue. Green dots represent control samples. Blue dots represent DXM samples. 'Scores t1' represents scores of samples on principal component 1 and 'scores t2' represents scores of samples on principal component 2. (B) OPLS-DA score plot. R2Y=0.985, Q2=0.961. Green dots represent control samples. Blue dots represent DXM samples. (C) Statistical validation of corresponding OPLS-DA model by permutation testing (200 iterations). (D) Volcano score plot based on corresponding OPLS-DA model. Blue dots are P≤0.05 and fold-change \<0. Red dots are P≤0.05 and fold change \>0. Green dots represent no statistically significant difference. The diameter of dots represents the VIP value. (E) PCA score plot of placenta tissue. Green dots represent control samples. Blue dots represent DXM samples. (F) OPLS-DA score plot. R2Y=0.999, Q2=0.592. Green dots represent control samples. Blue dots represent DXM samples. (G) Statistical validation of corresponding OPLS-DA model by permutation testing (200 iterations). (H) Volcano score plot based on corresponding OPLS-DA model. DXM, dexamethasone; OPLS-DA, orthogonal partial least squares discriminant analysis; PCA, principal component analysis; VIP, variable importance in projection.](MMR-20-04-3326-g06){#f7-mmr-20-04-3326}

###### 

Metabolite identification.

  Metabolite       Chemical shift
  ---------------- ------------------------------------
  Valine           0.99(d),3.72(t), 1.96(m), 0.91(d)
  Lactate          4.11(q), 1.32(d)
  Alanine          3.77(q), 1.48(d)
  Acetate          1.91(s)
  Glutamate        2.08(m), 2.34(m), 3.75(m)
  Glutamine        2.15(m), 2.44(m), 3.77(m)
  Citrate          2.55(d), 2.65(d)
  Creatinine       3.03(s), 3.92(s)
  Choline          3.2(s), 4.05(t), 3.51(t)
  Phosphocholine   3.22(s), 4.21(t), 3.61(t)
  TMAO             3.27(s)
  β-glucose        4.66(d)
  α-glucose        5.23(d)
  Succinate        2.41(s)
  Taurine          3.26(t), 3.40(t)
  Betaine          3.26(s), 3.93(s)
  Hippurate        3.98(d), 7.56(t), 7.65(t), 7.84(d)
  Leucine          3.65(d), 1.95(m), 0.94(t), 1.02(d)
  Glycine          3.57(s)

s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; dd, doublet of doublets; TMAO, trimethylamine N-oxide.

###### 

Statistical descriptions of water-soluble metabolites in palate and placenta tissues.

                           Palate tissue   Placenta tissue                                                                                              
  ------------------------ --------------- ----------------- ----------------- ----------------- -------- ------ ------ --------------- --------------- -------
  Leucine                  0.00            4.89              7649.21±3895.92   1957.82±1510.09   0.26     --     --     --              --              --
  Valine                   0.00            1.78              1050.90±2738.71   218.99±170.16     0.21     0.00   1.39   25.58±12.27     4.24±8.41       0.17
  Lactate                  0.00            1.67              68.35±26.84       918.34±977.56     13.44    0.00   5.55   516.03±276.06   120.48±255.53   0.23
  Alanine                  0.02            1.12              282.29±197.32     750.48±596.57     2.66     0.00   1.98   60.24±33.65     12.06±23.24     0.20
  Acetate                  0.00            1.70              1014.00±1056.01   130.01±156.89     0.13     --     --     --              --              --
  N-acetyl-glycoproteins   0.00            1.28              559.06±540.29     71.13±58.40       0.13     --     --     --              --              --
  Glutamate/glutathione    0.00            1.31              68.73±35.95       501.48±499.33     7.30     --     --     --              --              --
  Glutamate/glutamine      0.00            1.02              44.30±16.26       524.68±534.09     11.84    0.00   1.41   31.09±20.42     5.60±13.07      0.18
  Glutamine                0.02            1.25              69.47±41.33       793.78±988.57     11.43    --     --     --              --              
  Glutathione              0.00            1.10              36.97±19.61       3864.80±4236.00   104.54   --     --     --              --              --
  Citrate                  0.02            1.20              2183.87±2904.82   120.63±144.93     0.06     --     --     --              --              
  Creatinine + creatine    0.04            1.61              1081.13±1605.99   63.43±102.37      0.06     0.01   1.19   26.46±11.11     4.89±12.10      0.18
  Succinate                --              --                --                --                --       0.00   1.11   19.27±23.77     2.92±5.08       0.15
  Choline                  --              --                --                --                --       0.01   2.15   115.54±54.83    49.35±61.16     0.43
  Phosphocholine           0.05            1.17              47.36±35.40       590.87±905.90     12.48    0.00   4.50   321.47±190.61   50.34±142.88    0.16
  TMAO                     --              --                --                --                --       0.02   3.51   340.12±275.78   86.09±214.74    0.25
  Proline + inositol       0.03            2.44              338.04±342.57     2559.04±3299.32   7.57     0.01   1.41   3.26±6.07       35.69±38.47     10.93
  Phenylacetylglycine      --              --                --                --                --       0.00   1.21   24.95±2.61      2.61±6.44       0.10
  D-Glucose                --              --                --                --                --       0.01   1.04   25.01±16.76     6.99±14.33      0.28
  Betaine                  --              --                --                --                --       0.00   1.98   53.45±29.63     8.81±21.99      0.16
  Glycine                  0.00            1.17              556.24±527.30     97.10±157.17      0.17     --     --                     --              --

The average values are the area under the peak (without units). SD, standard deviation; TMAO, trimethylamine N-oxide; DXM, dexamethasone; VIP, variable importance in the projection.

###### 

Statistical descriptions of water-soluble metabolites in serum and amniotic fluid.

                    Amniotic fluid   Serum                                                                                       
  ----------------- ---------------- ------- --------------- --------------- ------ ------ ------ ------------- ---------------- --------
  Lactate           0.03             4.13    156.34±365.95   672.69±671.50   4.30   --     --     --            --               --
  Alanine           0.05             1.01    53.13±43.71     19.19±33.97     0.36   --     --     --            --               --
  Glutamine                                                                         0.01   1.48   28.56±34.67   0.87±2.74        0.03
  Citrate                                                                           0.05   1.04   5.61±8.06     23.65±28.33      4.21
  Creatinine        0.00             1.10    25.15±18.93     0.63±1.45       0.03   0.03   7.32   1.73±3.98     714.85±1029.54   412.54
  Phosphocholine    0.00             1.35    34.42±19.91     2.57±4.04       0.07   --     --     --            --               --
  Taurine/betaine   0.00             1.21    34.80±24.25     4.37±5.31       0.13   --     --     --            --               --
  Choline           0.00             1.35    55.77±50.54     9.08±11.23      0.16   --     --     --                             --
  Glycine           0.00             1.40    39.26±26.78     1.72±4.81       0.04   --     --     --            --               --
  Hippurate         0.00             1.20    52.22±34.88     15.26±25.45     0.29   --     --     --            --               --
  α-glucose         0.00             1.04    27.78±18.74     4.46±6.17       0.16   --     --     --            --               --

The average values are the area under the peak (without units). SD, standard deviation; DXM, dexamethasone; VIP, variable importance in the projection.

###### 

Statistical descriptions of lipid-soluble metabolites in palate and placenta tissues.

                              Placenta tissue   Palate tissue                                                                                         
  ------------- ------------- ----------------- --------------- --------------- ------------- ------- ------ ------ ---------------- ---------------- ------
  Cholesterol   26,27-CH~3~   0.00              2.58            195.36±145.18   23.36±51.59   0.74    0.00   1.01   67.47±232.96     493.15±203.86    7.30
                21-CH~3~      0.03              1.85            160.08±127.68   21.26±43.23   0.80    0.00   1.38   72.22±249.19     640.01±103.68    8.86
                19-CH~3~      0.00              1.03            25.61±17.37     3.30±8.92     0.80    --     --     --               --               --
                18-CH~3~      0.00              3.18            273.41±200.89   26.39±70.91   0.73    0.00   1.91   175.53±606.38    1319.61±169.66   7.51
  Ω3            CH~3~         0.00              4.73            249.26±122.32   24.19±85.85   0.50    --     --     --               --               --
  Lipids        CH~3~         0.00              2.83            3.24±58.20      0.58±53.55    17.93   0.02   1.32   977.91±1588.02   2140.05±238.69   2.19
                (CH~2~)n      --                --              --              --            0.28    0.00   2.11   1659.69±210.56   456.80±237.02    0.28
                CH~2~CH=C     0.00              1.78            3.01±23.81      1.22±19.29    7.90    --     --     --               --               --
                =CHCH~2~CH=   0.02              1.16            30.63±19.02     4.86±14.59    0.62    --     --     --               --               --
                CH=C          0.03              1.28            24.58±40.30     14.04±18.79   1.64    --     --     --               --               --

The average values are the area under the peak (without units). SD, standard deviation; DXM, dexamethasone; VIP, variable importance in the projection.

[^1]: Contributed equally
